ERBB2 and breast cancer: The monoclonal antibody trastuzumab has significantly improved outcomes for both early and advanced HER2-positive BC patients(Ban et al. 2020; Baselga et al. 2017; Kourie et al. 2017; Veeraraghavan et al. 2021).